Clinical Validation Data for Integrated TORCHes Pathogen Detection System

210 clinical samples were used to validate a novel diagnostic system for six TORCH pathogens. The study reports analytical metrics including limits of detection from 200 to 500 copies/mL and a 1-year room-temperature stability for freeze-dried reagents. The system was developed by Miao Fu and published in 2026, showing near-perfect agreement with commercial qPCR.

Use Cases

• Validate diagnostic sensitivity and specificity using the reported limits of detection (LoD) for HSV-I/II, HCMV, TOX, EBV, and RV.
• Analyze the stability of freeze-dried microspheres over a 1-year period at room temperature for reagent development.
• Compare pathogen typing results from the TORCHes-MCAv1.0 software against manual interpretation or Sanger sequencing data.
• Benchmark the integrated system's performance against commercial single-target qPCR using the 210 clinical sample validation results.

Strengths

• Clinical validation involved 210 samples, providing a substantive test set.
• Reports specific analytical performance metrics, including LoDs of 200 copies/mL for three pathogens and 500 copies/mL for two others.
• Freeze-dried reagents demonstrated stability at room temperature for 1 year, a key practical advantage.
• High agreement with reference methods, with Kappa statistics ranging from 0.965 to 1.000.

Limitations

• The dataset is very small in scale, consisting of a 101.0 KB document summarizing results rather than raw experimental data.
• No raw data tables, column definitions, or sample data are provided, limiting direct analytical reuse.
• The clinical sample provenance and geographic origin are not specified, which may limit generalizability.

Provenance

Source

Miao Fu, published on figshare.

Collection Method

Data generated from a clinical validation study comparing a novel integrated diagnostic system against commercial qPCR and Sanger sequencing.

Freshness

Last updated in March 2026, indicating recent publication.